Alembic Pharmaceuticals Faces Neutral Outlook Amid Declining Performance Metrics
Alembic Pharmaceuticals has experienced a recent evaluation adjustment, with its technical indicators reflecting a shift to a neutral position. The company has faced performance challenges over the past year, including a decline in stock returns and negative growth in operating profit, despite a strong debt servicing capability.
Alembic Pharmaceuticals has recently undergone an adjustment in its evaluation, reflecting shifts in various technical indicators. The stock's technical trend has transitioned from a mildly bullish stance to a more neutral position. Key metrics such as the MACD and KST are currently indicating a mildly bearish outlook on both weekly and monthly bases, while the Bollinger Bands also suggest a bearish trend.In terms of performance, Alembic Pharmaceuticals has faced challenges over the past year, with a notable decline in stock returns compared to the broader market. The company's operating profit has shown a negative growth rate over the last five years, contributing to a flat financial performance in the recent quarter. Despite a strong ability to service debt, as evidenced by a low Debt to EBITDA ratio, the overall financial landscape remains complex.
The stock is currently trading at a discount relative to its peers, and while institutional holdings are significant, the recent trends indicate a cautious approach to its evaluation.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
